Characters and Therapy of Triple-Negative Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

CHEN Yujuan , WANG Xiaodong , WANG Jing

Department of Thyroid and Breast Surgery，West China Hospital，Sichuan University，Chengdu 610041，Sichuan Province，China;

Corresponding author：

Keywords：

Triple-negative breast cancer; Diagnosis; Therapy

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To explore the characters and therapy of the triple-negative breast cancer （TNBC）.
Methods 　The pertinent literatures with key words “triple-negative breast cancer”，“diagnosis”，and “therapy” were retrieved and reviewed.
Results 　TNBC was a subtype of breast cancer characterized by negative expressions of estrogen receptor （ER），progesterone receptor （PR），and human epidermal growth factor receptor-2 （HER-2）. The clinicopathologic feature and prognosis of TNBC were distinct from other breast cancer. The age of onset was younger，disease free survival and total survival rate were lower in the patients with TNBC. At present， the therapy guideline was lack of TNBC，which referred to the non-TNBC，including local surgery，systemic chemotherapy，and the target therapy was at the clinical trial stage.
Conclusions 　TNBC is one of heterogeneity characteristics for the breast cancer，which has extra much difference. For improving the TNBC prognosis，we hope that more and more significant markers to TNBC in the future are found，which are useful to make individuation treatment.

Citation： CHEN Yujuan,WANG Xiaodong,WANG Jing. Characters and Therapy of Triple-Negative Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2012, 19(9): 1024-1027. doi: Copy

1.	Bauer KR， Brown M， Cress RD， et al. Descriptive analysis of estrogen receptor (ER)-negative， progesterone receptor (PR)-negative， and HER2-negative invasive breast cancer， the so-called triple-negative phenotype：a population-based study from the California Cancer Registry[J]. Cancer， 2007， 109(9)：1721-1728.
2.	Rakha EA， El-Sayed ME， Green AR， et al. Prognostic markers in triple-negative breast cancer[J]. Cancer， 2007， 109(1)： 25-32.
3.	Foulkes WD， Stefansson IM， Chappuis PO， et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer[J]. J Natl Cancer Inst， 2003， 95(19)：1482-1485.
4.	袁中玉，王树森，高岩，等. 305例三阴乳腺癌患者的临床特征及预后因素分析[J]. 癌症， 2008， 27(6)：561-565.
5.	Haffty BG， Yang Q， Reiss M， et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer[J]. J Clin Oncol， 2006， 24(36)：5652-5657.
6.	Perou CM， Sørlie T， Eisen MB， et al. Molecular portraits ofhuman breast tumours[J]. Nature， 2000， 406(6797)：747-752.
7.	Kim MJ， Ro JY， Ahn SH， et al. Clinicopathologic significance of the basal-like subtype of breast cancer：a comparison with hormone receptor and Her2/neu-overexpressing phenotypes[J]. Hum Pathol， 2006， 37(9)：1217-1226.
8.	Nielsen TO， Hsu FD， Jensen K， et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J]. Clin Cancer Res， 2004， 10(16)：5367-5374.
9.	Kandel MJ， Stadler Z， Masciari S， et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC)[J]. J ClinOncol， 2006， 24(18S)：508.
10.	Mullan PB， Quinn JE， Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control[J]. Oncogene， 2006， 25(43)：5854-5863.
11.	Turner N， Tutt A， Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers[J]. Nat Rev Cancer， 2004， 4(10)：814-819.
12.	Turner N， Tutt A， Ashworth A. Targeting the DNA repair defect of BRCA tumours[J]. Curr Opin Pharmacol， 2005， 5(4)：388-393.
13.	Byrski T， Gronwald J， Huzarski T， et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy[J]. J Clin Oncol， 2010， 28(3)：375-379.
14.	Byrski T， Huzarski T， Dent R， et al. Response to neoadjuvanttherapy with cisplatin in BRCA1-positive breast cancerpatients[J]. Breast Cancer Res Treat， 2009， 115(2)：359-363.
15.	Liedtke C， Mazouni C， Hess KR， et al. Differential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol， 2007， 25(18S)：10519.
16.	Millar EK， Graham PH， O’Toole SA， et al. Prediction of local recurrence， distant metastases， and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarkerpanel[J]. J Clin Oncol， 2009， 27(28)：4701-4708.
17.	Solin LJ， Hwang WT， Vapiwala N. Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma[J]. Clin Breast Cancer， 2009， 9(2)：96-100.
18.	Voduc KD， Cheang MC， Tyldesley S， et al. Breast cancer subtypes and the risk of local and regional relapse[J]. J Clin Oncol， 2010， 28(10)：1684-1691.
19.	Liedtke C， Mazouni C， Hess KR， et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol， 2008， 26(8)：1275-1281.
20.	Toi M， Nakamura S， Kuroi K， et al. PhaseⅡstudy of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival[J]. Breast Cancer Res Treat， 2008， 110(3)：531-539.
21.	Rouzier R， Perou CM， Symmans WF， et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J]. Clin Cancer Res， 2005， 11(16)：5678-5685.
22.	Esserman LJ， Perou C， Cheang M， et al. Breast cancer molecularprofiles and tumor response of neoadjuvant doxorubicin and paclitaxel：The I-SPY TRIAL (CALGB 150007/150012， ACRIN 6657)[J]. J Clin Oncol， 2009， 27(18S)：LBA515.
23.	Wang S， Yang H， Tong F， et al. Response to neoadjuvant therapyand disease free survival in patients with triple-negative breast cancer[J]. Gan To Kagaku Ryoho， 2009， 36(2)：255-258.
24.	Cass I， Baldwin RL， Varkey T， et al. Improved survival in women with BRCA-associated ovarian carcinoma[J]. Cancer， 2003， 97(9)：2187-2195.
25.	Weberpals JI， Clark-Knowles KV， Vanderhyden BC. Sporadic epithelial ovarian cancer：clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway[J]. J Clin Oncol， 2008， 26(19)：3259-3267.
26.	Chang HR， Slamon D， Gornbein JA， et al. Preferential pathologic complete response (pCR) by triple-negative (-) breast cancer to neoadjuvant docetaxel (T) and carboplatin (C)[J]. J ClinOncol， 2008， 26(15)：604.
27.	Torrisi R， Balduzzi A， Ghisini R， et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptornegative and HER2 negative) breast cancer with epirubicin， cisplatin， and infusional fluorouracil followed by weekly paclitaxel[J]. Cancer Chemother Pharmacol， 2008， 62(4)：667-672.
28.	Yerushalmi R， Hayes MM， Gelmon KA， et al. A phaseⅡtrial of a neoadjuvant platinum regimen for locally advanced breast cancer：pathologic response， long-term follow-up， and correlation with biomarkers[J]. Clin Breast Cancer， 2009， 9(3)：166-172.
29.	Sikov WM， Dizon DS， Strenger R， et al. Frequent pathologic complete responses in aggressive stagesⅡtoⅢbreast cancerswith every-4-week carboplatin and weekly paclitaxel with or without trastuzumab：a Brown University Oncology Group Study[J]. J Clin Oncol， 2009， 27(28)：4693-4700.
30.	Oliveras-Ferraros C， Vazquez-Martin A， López-Bonet E， et al. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib resistant MDA-MB-468 cells：new prospects in the treatment of triple-negative/basal-like breast cancer[J]. Int J Oncol， 2008， 33(6)：1165-1176.
31.	Ueno NT， Zhang D. Targeting EGFR in triple negative breast cancer[J]. J Cancer， 2011， 2：324-328.
32.	Pal SK， Childs BH， Pegram M. Triple negative breast cancer：unmet medical needs[J]. Breast Cancer Res Treat， 2011， 125(3)：627-636.
33.	Sahin I， Ararat E， Altundag K. BRCA-deficient and triple negative breast cancers：is olaparib effective in both subtypes? [J]. J BUON， 2011， 16(1)：184-185.

1. Bauer KR， Brown M， Cress RD， et al. Descriptive analysis of estrogen receptor (ER)-negative， progesterone receptor (PR)-negative， and HER2-negative invasive breast cancer， the so-called triple-negative phenotype：a population-based study from the California Cancer Registry[J]. Cancer， 2007， 109(9)：1721-1728.
2. Rakha EA， El-Sayed ME， Green AR， et al. Prognostic markers in triple-negative breast cancer[J]. Cancer， 2007， 109(1)： 25-32.
3. Foulkes WD， Stefansson IM， Chappuis PO， et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer[J]. J Natl Cancer Inst， 2003， 95(19)：1482-1485.
4. 袁中玉，王树森，高岩，等. 305例三阴乳腺癌患者的临床特征及预后因素分析[J]. 癌症， 2008， 27(6)：561-565.
5. Haffty BG， Yang Q， Reiss M， et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer[J]. J Clin Oncol， 2006， 24(36)：5652-5657.
6. Perou CM， Sørlie T， Eisen MB， et al. Molecular portraits ofhuman breast tumours[J]. Nature， 2000， 406(6797)：747-752.
7. Kim MJ， Ro JY， Ahn SH， et al. Clinicopathologic significance of the basal-like subtype of breast cancer：a comparison with hormone receptor and Her2/neu-overexpressing phenotypes[J]. Hum Pathol， 2006， 37(9)：1217-1226.
8. Nielsen TO， Hsu FD， Jensen K， et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J]. Clin Cancer Res， 2004， 10(16)：5367-5374.
9. Kandel MJ， Stadler Z， Masciari S， et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC)[J]. J ClinOncol， 2006， 24(18S)：508.
10. Mullan PB， Quinn JE， Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control[J]. Oncogene， 2006， 25(43)：5854-5863.
11. Turner N， Tutt A， Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers[J]. Nat Rev Cancer， 2004， 4(10)：814-819.
12. Turner N， Tutt A， Ashworth A. Targeting the DNA repair defect of BRCA tumours[J]. Curr Opin Pharmacol， 2005， 5(4)：388-393.
13. Byrski T， Gronwald J， Huzarski T， et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy[J]. J Clin Oncol， 2010， 28(3)：375-379.
14. Byrski T， Huzarski T， Dent R， et al. Response to neoadjuvanttherapy with cisplatin in BRCA1-positive breast cancerpatients[J]. Breast Cancer Res Treat， 2009， 115(2)：359-363.
15. Liedtke C， Mazouni C， Hess KR， et al. Differential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol， 2007， 25(18S)：10519.
16. Millar EK， Graham PH， O’Toole SA， et al. Prediction of local recurrence， distant metastases， and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarkerpanel[J]. J Clin Oncol， 2009， 27(28)：4701-4708.
17. Solin LJ， Hwang WT， Vapiwala N. Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma[J]. Clin Breast Cancer， 2009， 9(2)：96-100.
18. Voduc KD， Cheang MC， Tyldesley S， et al. Breast cancer subtypes and the risk of local and regional relapse[J]. J Clin Oncol， 2010， 28(10)：1684-1691.
19. Liedtke C， Mazouni C， Hess KR， et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol， 2008， 26(8)：1275-1281.
20. Toi M， Nakamura S， Kuroi K， et al. PhaseⅡstudy of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival[J]. Breast Cancer Res Treat， 2008， 110(3)：531-539.
21. Rouzier R， Perou CM， Symmans WF， et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J]. Clin Cancer Res， 2005， 11(16)：5678-5685.
22. Esserman LJ， Perou C， Cheang M， et al. Breast cancer molecularprofiles and tumor response of neoadjuvant doxorubicin and paclitaxel：The I-SPY TRIAL (CALGB 150007/150012， ACRIN 6657)[J]. J Clin Oncol， 2009， 27(18S)：LBA515.
23. Wang S， Yang H， Tong F， et al. Response to neoadjuvant therapyand disease free survival in patients with triple-negative breast cancer[J]. Gan To Kagaku Ryoho， 2009， 36(2)：255-258.
24. Cass I， Baldwin RL， Varkey T， et al. Improved survival in women with BRCA-associated ovarian carcinoma[J]. Cancer， 2003， 97(9)：2187-2195.
25. Weberpals JI， Clark-Knowles KV， Vanderhyden BC. Sporadic epithelial ovarian cancer：clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway[J]. J Clin Oncol， 2008， 26(19)：3259-3267.
26. Chang HR， Slamon D， Gornbein JA， et al. Preferential pathologic complete response (pCR) by triple-negative (-) breast cancer to neoadjuvant docetaxel (T) and carboplatin (C)[J]. J ClinOncol， 2008， 26(15)：604.
27. Torrisi R， Balduzzi A， Ghisini R， et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptornegative and HER2 negative) breast cancer with epirubicin， cisplatin， and infusional fluorouracil followed by weekly paclitaxel[J]. Cancer Chemother Pharmacol， 2008， 62(4)：667-672.
28. Yerushalmi R， Hayes MM， Gelmon KA， et al. A phaseⅡtrial of a neoadjuvant platinum regimen for locally advanced breast cancer：pathologic response， long-term follow-up， and correlation with biomarkers[J]. Clin Breast Cancer， 2009， 9(3)：166-172.
29. Sikov WM， Dizon DS， Strenger R， et al. Frequent pathologic complete responses in aggressive stagesⅡtoⅢbreast cancerswith every-4-week carboplatin and weekly paclitaxel with or without trastuzumab：a Brown University Oncology Group Study[J]. J Clin Oncol， 2009， 27(28)：4693-4700.
30. Oliveras-Ferraros C， Vazquez-Martin A， López-Bonet E， et al. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib resistant MDA-MB-468 cells：new prospects in the treatment of triple-negative/basal-like breast cancer[J]. Int J Oncol， 2008， 33(6)：1165-1176.
31. Ueno NT， Zhang D. Targeting EGFR in triple negative breast cancer[J]. J Cancer， 2011， 2：324-328.
32. Pal SK， Childs BH， Pegram M. Triple negative breast cancer：unmet medical needs[J]. Breast Cancer Res Treat， 2011， 125(3)：627-636.
33. Sahin I， Ararat E， Altundag K. BRCA-deficient and triple negative breast cancers：is olaparib effective in both subtypes? [J]. J BUON， 2011， 16(1)：184-185.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Characters and Therapy of Triple-Negative Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content